ADArtem R. Dorotenko

Artem R. Dorotenko

*This is an algorithmically generated author record based on publicly available information.

Artem R. Dorotenko has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ceralasertib as second- or third-line therapy for advanced or metastatic non-small-cell lung cancer without actionable genomic alterations (LOTOS): a multicenter, single-arm, phase 2 trial

    by Artem R. Dorotenko, Доротенко Артем Романович, Mariia S. Shustova, Шустова Мария Станиславовна, Andrey V. Vlasenko, Власенко Андрей Валерьеви, Alexey S. Kiselev, Киселев Алексей Сергеевич, Maria E. Blokhina, Блохина Мария Евгеньевна, et al.

    Background. Despite improved outcomes with immune checkpoint inhibitors in first- or second-line advanced non-small-cell lung cancer (NSCLC) settings, a significant patient population has emerged that either does not respond to or progresses during anti-PD-(L)1-containing therapy. Following progression on platinum-based chemotherapy and PD-(L)1 inhibitor therapies, treatment options for patients with NSCLC are limited. Aim. To evaluate the clinical efficacy and safety of ceralasertib combined with durvalumab for the treatment of advanced or metastatic NSCLC without actionable genomic alterations. Materials and methods. This multicenter, single-arm, phase II study (NCT05941897; randomized clinical trial No. 88, dated February 21, 2023) conducted in Russia enrolled patients with EGFR and ALK wild-type NSCLC who had progressed on first- or second-line platinum-doublet chemotherapy and anti-PD-(L)1 immunotherapy. Eligible patients received oral ceralasertib 240 mg twice daily for 7 consecutive days followed by durvalumab 1500 mg as an intravenous infusion in continuous 28-day treatment cycles until disease progression, unacceptable toxicity, or death. The primary endpoint was investigator-assessed objective response rate (ORR). Secondary endpoints included disease control rate at 18 weeks (DCR), progression-free survival (PFS), duration of response, overall survival (OS), and safety. Results. Between June 2023 and July 2025, 55 patients were screened, of whom 39 received ceralasertib plus durvalumab. The median follow-up time was approximately 9 months. The confirmed ORR was 10.3% (4/39; 95% confidence interval [CI] 2.9–24.2), and DCR was 53.8% (21/39; 95% CI 37.2–69.9). Median PFS was 6.41 months (95% CI 3.71–8.28) and median OS was 18.04 months (95% CI 8.84–23.23). Adverse events (AEs) were reported in 31 patients (79.5%), with 11 (28.2%) experiencing grade ≥3 events. The most common AEs were nausea (53.8%), vomiting (23.1%), respiratory tract infection (20.5%), anemia (15.4%), asthenia (15.4%), fatigue (15.4%), and diarrhea (12.8%). No treatment-related serious adverse events or deaths occurred. Conclusion. The combination of ceralasertib and durvalumab demonstrated a manageable safety profile with clinical activity (as evidenced by PFS and OS) in second- or third-line treatment of patients with advanced or metastatic NSCLC without actionable genomic alterations. These findings support further investigation of this combination in selected patient populations.

  • Open Access

    Efficacy of salbutamol and budesonide metered-dose inhaler in preventing exercise-induced bronchoconstriction in patients with mild asthma

    by A. R. Dorotenko, M. S. Shustova, E. A. Orlova, M. V. Vershinina, A. B. Peskov, Yu. G. Schwartz, L. I. Sursiakova, R. T. Sardinov, Ю. Г. Шварц

    Budesonide/albuterol (salbutamol) combination (BDA) is a fixed combination of salbutamol (albuterol) and budesonide in the form of a metereddose aerosol for inhalation, the efficacy and safety of which have been demonstrated by several international phase III clinical trials in adults, adolescents, and children with asthma. This clinical trial is part of a program to study BDA in asthma patients with exercise-induced bronchospasm (EIB).The aim of the study was to evaluate the efficacy and safety of budesonide/salbutamol compared with placebo in patients with asthma and EIB.Methods. Adult patients with EIB (defined as a fall in forced expiratory volume in 1 second (FEV1) ≥ 20% from pre-exercise (PE) values) participating in a double-blind, crossover study were randomized to a single dose of study medication in the sequence BDA (160/180 mcg)/placebo (n = 31) or the reverse sequence (n = 33). Serial FEV1 measurements were made 5 min before and 30 min after drug administration (i.e., 5 min before the treadmill exercise challenge (ECT); baseline) and 5, 10, 15, 30, and 60 min after PE. The primary efficacy endpoint was the maximum percentage fall in FEV1 from baseline at 60 min after ECT.Results. With BDA, the mean maximum percentage of FEV1 decline within 60 minutes after ECT was 6.95% vs 22.4% with placebo (the difference between the drugs was 17.52% (95% confidence interval was 15.25 – 19.78%; p < 0.001). The protective effect in preventing EIB (determined by the maximum decline in FEV1 after ECT < 10%) was achieved in a greater number of patients after BDA compared with placebo (75.0% and 3.1%, respectively; p < 0.001). The effect was demonstrated both in the overall study population and in the subpopulations of patients who received and did not receive inhaled corticosteroids. The single dose of BDA showed satisfactory tolerability in the study.Conclusion. The study results confirmed the possibility of using BDA (160/180 mcg) as a new and effective pharmacological method to prevent EIB.

  • Open Access

    Phosphodiesterase 10A as a Therapeutic Target in Neuropsychopharmacology: A Review

    by A. R. Dorotenko, I. M. Sukhanov, G. V. Iskarevskii, A. S. Ulitina, A. A. Savchenko, M. А. Tur

    INTRODUCTION. Phosphodiesterases (PDEs) are enzymes that regulate intracellular signalling by catalysing the hydrolysis of cyclic nucleotides. The commercial success of selective PDE5 inhibitors for erectile dysfunction and PDE4 inhibitors for respiratory and skin diseases has drawn the close attention of pharmaceutical companies to other PDEs as well. PDE10A, which is expressed in medium spiny neurons (MSNs) of the striatum, deserves special attention as a promising target in psychopharmacology.AIM. This study aimed to analyse existing preclinical and clinical data on the use of PDE10A inhibitors and to assess possible barriers to the development of medicinal products of this class in neuropsychopharmacology.DISCUSSION. Preclinical studies have shown that PDE10A inhibitors, which increase the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in MSNs, have antipsychotic and antiparkinsonian properties. Some researchers also believe that PDE10A inhibitors improve cognitive functions. Despite the promising results of preclinical studies, clinical trials of PDE10A inhibitors have not been successful. This review analyses the possible reasons for these failures, including a poor understanding of the function of striatal PDEs in both normal and pathological conditions, the possible development of tolerance to some effects of PDEs, the complex interactions of intracellular cAMP and cGMP signalling pathways, and the intricate workings of the cortico-striato-thalamo-cortical (CSTC) circuits.CONCLUSIONS. Further research is needed to fully assess the therapeutic potential of PDE10A inhibitors, with a more detailed investigation of the mechanism of action of PDEs, the activity of MSNs, and the CSTC circuits. New data at these three levels of study (subcellular, cellular, and systemic) will create conditions for further development of PDE10A inhibitors.

  • Open Access

    Tolerance to paradoxical increase in motor activity caused by inhibition of phosphodiesterase 10a in a model of hypodopaminergy

    by A. R. Dorotenko, I. M. Sukhanov, A. A. Savchenko, O. A. Dravolina, I. V. Belozertseva

    Introduction. Phosphodiesterases (PDEs) are a group of enzymes that hydrolyze the phosphodiester bond in cyclic nucleotides. PDE10A is mainly present in the medium-sized spiny neurons of the striatum. Functionally, PDE10A inhibition imitates the effect of D1-like agonists and D2-like dopamine receptor antagonists, and simultaneously modulating “direct” and “indirect” striato-thalamo-cortical brain pathway. To date, the effects of PDE10A inhibition have been characterized mainly, reproducing the inhibitory motor activity of D2-like dopamine receptor antagonists.The objective was to evaluate the stimulating motor activity of the effect of PDE10A inhibitors, as well as the possible development of tolerance to these effects when they are re-administered.Methods and materials. The hypodopaminergic state in male Wistar stock rats was modeled by administration of the VMAT2 inhibitor tetrabenazine (3 mg/kg). The effects of selective inhibitors PDE10A, MP-10 (0.3–5 mg/kg) and RO5545965 (0.1–0.9 mg/kg), on the motor activity of rats were evaluated with single and repeated administration (5 and 10 days).Results. Switching off PDE10A dose-dependently stimulated the motor activity of rats after administration of tetrabenazine. However, repeated administration of PDE10A inhibitors was accompanied by the development of tolerance to their paradoxical stimulating effect.Conclusion. The development of tolerance may limit the potential clinical use of PDE10A inhibitors to correct hypodopaminergic symptoms in patients with Parkinson’s disease. It is necessary to study the molecular mechanism of this phenomenon.


  • Open Access

    An Open-label Randomized Crossover Study with Adaptive Design of the Pharmacokinetics and Bioequivalence of GP30121 and Ceraxon® Corrected for Endogenous Analyte Level

    by A. N. Arevefa, A. R. Dorotenko, S. M. Noskov, I. E. Makarenko, R. V. Drai, T. N. Komarov, O. A. Archakova, N. S. Bagaeva, I. E. Shokhin

    Introduction. Citicoline is an endogenous nucleoside consisting of cytidine and choline linked by a diphosphate bridge that is involved in the synthesis of membrane phospholipids. Drugs containing citicoline have neuroprotective and neurometabolic effects and are used for the treatment of a wide range of neurological disorders. In its turn, bioequivalence study is a pathway to register a generic citicoline drug in Russian Federation.Aim. The aim of the study was to investigate the comparative pharmacokinetics (PK) and bioequivalence of two citicoline-containing drugs GP30121 and Ceraxon® in healthy male volunteers when taken on an empty stomach.Materials and methods. We evaluated the pharmacokinetics of citicoline-containing drugs corrected for endogenous analyte (uridine) level using an adaptive design. We determined uridine concentration by high-performance liquid chromatography with mass spectrometric detection. We used R Project software, version 3.6.3. for performing statistical analysis for the study.Results and discussion. GP30121 and Ceraxon® exhibited similar PK profiles. It was shown that the values of 94.12 % confidence interval (CI) at α = 0.0294 for the geometric mean ratios for the primary PK parameters of the main metabolite of the active ingredient of the investigated drugs were fully contained within the predefined equivalence limits of 80.00–125.00 %.Conclusion. The study demonstrates bioequivalence of GP30121 and Ceraxon® proving the approach with the correction for endogenous analyte could be considered in studies of other drugs.


  • Open Access

    Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson’s Disease Therapy

    by Ilya Sukhanov, Artem Dorotenko, Zoia Fesenko, Artem Savchenko, Evgeniya V. Efimova, Mikael S. Mor, Irina V. Belozertseva, Tatyana D. Sotnikova, Raul R. Gainetdinov

    Parkinson’s disease is the second most common neurodegenerative pathology. Due to the limitations of existing therapeutic approaches, novel anti-parkinsonian medicines with non-dopamine mechanisms of action are clearly needed. One of the promising pharmacological targets for anti-Parkinson drug development is phosphodiesterase (PDE) 10A. The stimulating motor effects of PDE10A inhibition were detected only under the conditions of partial dopamine depletion. The results raise the question of whether PDE10A inhibitors are able to restore locomotor activity when dopamine levels are very low. To address this issue, we (1) developed and validated the rat model of acute severe dopamine deficiency and (2) tested the action of PDE10A inhibitor MP-10 in this model. All experiments were performed in dopamine transporter knockout (DAT-KO) rats. A tyrosine hydroxylase inhibitor, α-Methyl-DL-tyrosine (αMPT), was used as an agent to cause extreme dopamine deficiency. In vivo tests included estimation of locomotor activity and catalepsy levels in the bar test. Additionally, we evaluated the tissue content of dopamine in brain samples by HPLC analysis. The acute administration of αMPT to DAT-KO rats caused severe depletion of dopamine, immobility, and catalepsy (Dopamine-Deficient DAT-KO (DDD) rats). As expected, treatment with the L-DOPA and carbidopa combination restored the motor functions of DDD rats. Strikingly, administration of MP-10 also fully reversed immobility and catalepsy in DDD rats. According to neurochemical studies, the action of MP-10, in contrast to L-DOPA + carbidopa, seems to be dopamine-independent. These observations indicate that targeting PDE10A may represent a new promising approach in the development of non-dopamine therapies for Parkinson’s disease.


  • The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats

    by Artem Dorotenko, Margarita Tur, Antonina Dolgorukova, Nikita Bortnikov, Irina V. Belozertseva, Edwin E. Zvartau, Raul R. Gainetdinov, Ilya Sukhanov

    Trace amine-associated receptor 1 (TAAR1) is a widely recognized new perspective target for the neuropsychiatric pharmacological treatment. Despite a growing number of studies investigating TAAR1 role in the animal models of different pathologies, information of TAAR1 agonists impact on executive cognitive functions is limited. The goal of the present study was to evaluate the activity of highly selective partial TAAR1 agonist RO5263397 on various executive cognitive functions. The results of the present study demonstrated that the pretreatment with RO5263397 was able to increase attention and decrease cognitive flexibility in rats. The analysis of the RO5263397 action on impulsivity demonstrated that the TAAR1 activation failed to affect premature responding but was able to slightly modify impulsive choice. Problem solving was resistant to the pharmacological intervention.


  • Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats

    by Ilya Sukhanov, Artem Dorotenko, Antonina Dolgorukova, Marius C. Hoener, Raul R. Gainetdinov, Anton Yu. Bespalov


  • Open Access

    Trace Amine-Associated Receptor 1 Modulates the Locomotor and Sensitization Effects of Nicotine

    by Ilya Sukhanov, Mariia Dorofeikova, Antonina Dolgorukova, Artem Dorotenko, Raul R. Gainetdinov

    Trace amine-associated receptor 1 (TAAR1) has emerged as a promising target for addiction treatments because it affects dopamine transmission in the mesolimbic pathway. TAAR1 is involved in the effects of addictive drugs, such as amphetamines, cocaine and ethanol, but the impact of TAAR1 on the effects of nicotine, the psychoactive drug responsible for the development and maintenance of tobacco smoking, has not yet been studied. This study was performed to investigate the possible modulatory action of TAAR1 on the effects of nicotine on locomotor behaviors in rats and mice. Pretreatment with the TAAR1 agonist RO5263397 dose-dependently decreased nicotine-induced hyperlocomotion in rats habituated to locomotor boxes, prevented the development of nicotine sensitization and blocked hypermotility in nicotine-sensitized rats at the highest tested dose (10 mg/kg). The lack of TAAR1 failed to affect the effects of nicotine on the locomotion of mutant mice. Based on the results of the present study, TAAR1 activation attenuates the locomotion-stimulating effects of nicotine on rats. These results further support the previously proposed hypothesis that TAAR1 is a promising target for the prevention and treatment of drug addiction. Further studies aimed at analyzing the effects of TAAR1 agonists on animal models of nicotine addiction are warranted.